ライフサイエンスコーパス: SMVT

1 SMVT represents the first Na+-dependent vitamin transpor

2 In the per-protocol analysis, SMVT recurrence at 6 months postablation reached statist

3 Patients with structural heart disease and SMVT documented by an ICD-EG, undergoing ablation, were

4 vement due to high-risk genetic variants and SMVT treated by electrophysiological study were recruite

5 ates significant sequence similarity between SMVT and known members of the Na+-dependent glucose tran

6 ng initial ICD therapy was predicted only by SMVT cycle length <250 ms at electrophysiologic testing.

7 patients experienced recurrences of clinical SMVT with differences between genotypes (log-rank 0.016)

8 om spontaneous SMVT to target the "clinical" SMVT for ablation.

9 The location of the clinical-SMVT substrate was significantly different based on geno

10 lity to distinguish morphologically distinct SMVT and can be used for pace mapping.

11 structural heart disease and ICD-documented SMVT, using ICD-EG information during the ablation proce

12 on (65%), with complementary ablation during SMVT in 26%, showing no significant difference between g

13 Ablation could be performed during SMVT (if tolerated), during sinus rhythm ("substrate abl

14 tests on mean and variance heterogeneities (SMVT), but the likelihood ratio test (LRT) severely infl

15 The human SMVT exhibits a high degree of homology (84% identity an

16 on and chromosomal localization of the human SMVT gene.

17 The human SMVT, when expressed in Xenopus laevis oocytes, induces

18 associated with a nonsignificant decrease in SMVT recurrence rate, a significant reduction in the num

19 The ICD-EG obtained during induced SMVT and pace mapping was compared to ICD-EG from sponta

20 Characterization of induced SMVT as clinical/nonclinical and pace mapping were more

21 e valve surgery were found to have inducible SMVT.

22 ial VT was the most common type of inducible SMVT in patients with valvular heart disease.

23 tained BBR VT was the only type of inducible SMVT.

24 entire follow-up period (44 +/- 29 months), SMVT recurrence occurred in 67% and 76% (HR: 0.80; 95% C

25 induced at electrophysiology study in 78% of SMVT patients, 48% of NSVT patients, and 4% of PVCs pati

26 sented with the index clinical arrhythmia of SMVT, 46 (36%) with NSVT, and 45 (35%) with PVCs.

27 n-to-treat analysis, the primary endpoint of SMVT recurrence within 6 months postablation occurred in

28 eous termination of 20 different episodes of SMVT (lasting 30 seconds to 10 minutes) from 8 dogs, 4 t

29 The number of SMVT episodes was significantly lower in the interventio

30 s) provide the only available information on SMVT.

31 patients presenting with resuscitated SCD or SMVT and incrementally identifies clinically unsuspected

32 Eighty-two patients with resuscitated SCD or SMVT underwent routine non-CMR imaging, followed by a CM

33 imaging in patients with resuscitated SCD or SMVT.

34 ping was compared to ICD-EG from spontaneous SMVT to target the "clinical" SMVT for ablation.

35 s preceded spontaneous termination of stable SMVT.

36 stained monomorphic ventricular tachycardia (SMVT) are frequently associated with prior or acute myoc

37 stained monomorphic ventricular tachycardia (SMVT) are suboptimal.

38 stained monomorphic ventricular tachycardia (SMVT) in 68%.

39 stained monomorphic ventricular tachycardia (SMVT), 2) repetitive nonsustained ventricular tachycardi

40 stained monomorphic ventricular tachycardia (SMVT), in the postinfarction heart, generally considered

41 stained monomorphic ventricular tachycardia (SMVT), when it develops after valve surgery, have not be

42 stained monomorphic ventricular tachycardia (SMVT).

43 Northern blot analysis shows that SMVT transcripts are present in all of the tissues that

44 The SMVT gene is approximately 14 kilobase pairs in length a

45 The SMVT gene is located on chromosome 2p23 as evidenced by

46 likely to be induced during exercise in the SMVT (10 of 15 patients [67%]) than NSVT or PVCs groups

47 (sodium-dependent multivitamin transporter (SMVT)) predicts a protein of 68.6 kDa with 634 amino aci

48 uman Na+-dependent multivitamin transporter (SMVT), which transports the water-soluble vitamins panto

49 Three transporters, SMVT (sodium-dependent multivitamin transporter for biot

50 quent symptoms, and patients presenting with SMVT and asymptomatic first ICD therapy are at very low

51 y tends to occur in patients presenting with SMVT and LVEF < or =25%.

52 for ICD therapy in patients presenting with SMVT versus cardiac arrest (CA) was 2.57 (range, 1.32 to